| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 101 | Heteromultivalent particle compositions | US14827785 | 2015-08-17 | US09833518B2 | 2017-12-05 | Anirban Sen Gupta; Madhumitha Ravikumar; Christa Modery |
| A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle or microparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle or microparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety. | ||||||
| 102 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO | US15309177 | 2015-05-07 | US20170151307A1 | 2017-06-01 | Randall J Mrsny; Tahir Mahmood |
| The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. | ||||||
| 103 | DEVICES FOR CONTROLLING MAGNETIC NANOPARTICLES TO TREAT FLUID OBSTRUCTIONS | US15155386 | 2016-05-16 | US20170095675A1 | 2017-04-06 | Francis M. Creighton |
| A system for the physical manipulation of free magnetic rotors in a circulatory system using a remotely placed magnetic field-generating stator is provided. In one embodiment, the invention relates to the control of magnetic particles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. Examples of vascular occlusions targeted by the system include, but are not limited to, atherosclerotic plaques, including fibrous caps, fatty buildup, coronary occlusions, arterial stenosis, restenosis, vein thrombi, arterial thrombi, cerebral thrombi, embolisms, hemorrhages, other blood clots, and very small vessels. | ||||||
| 104 | FUSION PROTEIN FOR TREATING REJECTION REACTION IN TRANSPLANTATION | US15253907 | 2016-09-01 | US20170056521A1 | 2017-03-02 | Tse-Wen CHANG; Hsing-Mao CHU; Li-Yun DU |
| The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed. | ||||||
| 105 | MULTI-ARM LINKER FOR TREATING REJECTION REACTION IN TRANSPLANTATION | US15253904 | 2016-09-01 | US20170056520A1 | 2017-03-02 | Tse-Wen CHANG; Hsing-Mao CHU; Chun-Yu LIN; Wei-Ting TIAN |
| The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed. | ||||||
| 106 | Multi-arm linker constructs for treating pathological blood clots | US15212298 | 2016-07-18 | US20170056517A1 | 2017-03-02 | Tse-Wen Chang; Hsing-Mao Chu; Chun-Yu Lin |
| The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed. | ||||||
| 107 | GELATINASE INHIBITORS AND PRODRUGS | US15139055 | 2016-04-26 | US20160346247A1 | 2016-12-01 | Mayland CHANG; Shahriar MOBASHERY; Mijoon LEE |
| The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration. | ||||||
| 108 | AMINOFUCOIDAN AS A VECTOR FOR FIBRINOLYSIS IN THROMBOTIC DISEASES | US14778259 | 2014-03-21 | US20160279249A1 | 2016-09-29 | Stephane LOYAU; Martine JANDROT-PERRUS; Didier LETOURNEUR; Frederic CHAUBET; Benoit HO-TIN-NOE; Murielle MAIRE; Jean-Baptiste MICHEL |
| The invention relates to a vector targeting thrombus, having t-PA binding property consisting of a thrombus targeting fucoidan moiety, which is covalently linked to one or more t-PA binding amino groups by the reducing end of the said fucoidan moiety. | ||||||
| 109 | PKC ACTIVATORS AND ANTICOAGULANT IN REGIMEN FOR TREATING STROKE | US14818576 | 2015-08-05 | US20160184414A1 | 2016-06-30 | Daniel L. Alkon |
| The present disclosure provides a method for treating stroke by administering to a subject an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator followed by adminstration of at least one PKC activator for a duration of treatment. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are kits comprising rTPA and a PKC activator for treating stroke. | ||||||
| 110 | Methods of controlling magnetic nanoparticles to improve vascular flow | US14581775 | 2014-12-23 | US09345498B2 | 2016-05-24 | Francis M. Creighton |
| Some embodiments provide a system for external manipulation of magnetic nanoparticles in vasculature using a remotely placed magnetic field-generating stator. In one aspect, the systems and methods relate to the control of magnetic nanoparticles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. | ||||||
| 111 | Control of magnetic rotors to treat therapeutic targets | US14268244 | 2014-05-02 | US09339664B2 | 2016-05-17 | Francis M. Creighton |
| A system for the physical manipulation of free magnetic rotors in a circulatory system using a remotely placed magnetic field-generating stator is provided. In one embodiment, the invention relates to the control of magnetic particles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. Examples of vascular occlusions targeted by the system include, but are not limited to, atherosclerotic plaques, including fibrous caps, fatty buildup, coronary occlusions, arterial stenosis, restenosis, vein thrombi, arterial thrombi, cerebral thrombi, embolisms, hemorrhages, other blood clots, and very small vessels. | ||||||
| 112 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MAMMALS HAVING LUNG ADENOCARCINOMA CHARACTERIZED BY NEUROENDOCRINE DIFFERENTIATION | US14773488 | 2014-03-07 | US20160018399A1 | 2016-01-21 | Farhad Kosari; George Vasmatzis; Marie-Christine Aubry; Cristiane M. Ida |
| This document provides methods and materials involved in identifying mammals having lung adenocarcinoma characterized by neuroendocrine differentiation as well as methods and materials involved in treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation. For example, methods and materials for using ASCL1 and RET expression levels to identify lung cancer patients having lung adenocarcinoma characterized by neuroendocrine differentiation are provided. | ||||||
| 113 | METHODS OF CONTROLLING MAGNETIC NANOPARTICLES TO IMPROVE VASCULAR FLOW | US14581775 | 2014-12-23 | US20150374395A1 | 2015-12-31 | Francis M. Creighton |
| Some embodiments provide a system for external manipulation of magnetic nanoparticles in vasculature using a remotely placed magnetic field-generating stator. In one aspect, the systems and methods relate to the control of magnetic nanoparticles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. | ||||||
| 114 | GLAUCOMA TREATMENT | US14766854 | 2014-02-12 | US20150366953A1 | 2015-12-24 | John DANIAS; Oscar A. CANDIA; Rosana GEROMETTA |
| Disclosed herein are methods of treatment for an intraocular pressure (IOP)-associated condition in a subject, that include administering to the subject an effective amount of a tissue plasminogen activator (tPA) therapeutic agent. In one embodiment, the IOP-associated condition is glaucoma. The administration of a tPA therapeutic agent can be an extended administration intended to cause a reduction in IOP in the subject for a period of at least one day to a year or more, relative to IOP levels in the subject prior to administration of the tPA therapeutic agent. The tPA therapeutic agent can be, for example, tPA, a tPA derivative, a small molecule direct or indirect tPA agonist, or a gene therapy vector. | ||||||
| 115 | PEPTIDE DIRECTED PROTEIN KNOCKDOWN | US14431060 | 2013-09-27 | US20150266935A1 | 2015-09-24 | Yu Tian Wang; Shelly Xuelai Lan; Wuyang Jin Jin |
| In one aspect, the invention provides a peptide comprising a chaperone-mediated autophagy (CMA)-targeting signal domain; a protein-binding domain that selectively binds to a target cytosolic protein; and a cell membrane penetrating domain (CMPD). In another aspect, the invention provides methods for reducing the intracellular expression level of an endogenous target protein in vitro and in an animal, wherein the method involves administration of the peptide. Methods are also provided for treating a pathological condition in an animal, the methods comprising administering the peptide to the animal. In one embodiment, the pathological condition is a neurodegenerative disease. In another embodiment of the invention, the target cytosolic protein is death associated protein kinase 1 and the CMPD is protein transduction domain of the HIV-1 Tat protein. | ||||||
| 116 | PLASMINOGEN ACTIVATOR MUTANTS AS ANTIFIBRINOLYTIC AGENTS | US14412873 | 2013-07-02 | US20150190482A1 | 2015-07-09 | Abd Higazi; Nuha Hijazi |
| The invention relates to an anti fibrinolytic composition comprising at least one tPA mutant that carries at least one point mutation substituting Ser481 to Ala on tPA, said mutant inhibits the fibrinolytic activity of at least one of tPA and uPA and therefore may be used for treating disorders associated with fibrinolytic processes, specifically, coagulopathies, thrombocytopenia and bleeding. The invention further provides methods and uses of the mutants of the invention. | ||||||
| 117 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF | US14342164 | 2012-09-07 | US20150050264A2 | 2015-02-19 | Denis VIVIEN; Jerome PARCQ |
| The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases. | ||||||
| 118 | Gelatinase inhibitors and prodrugs | US13582678 | 2011-03-04 | US08937151B2 | 2015-01-20 | Mayland Chang; Shahriar Mobashery; Mijoon Lee |
| The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration. | ||||||
| 119 | Pharmaceutical Compositions and Methods for Digesting Atherosclerotic Plaques | US14326904 | 2014-07-09 | US20140322190A1 | 2014-10-30 | Melina R. Kibbe; Guillermo A. Ameer; Vinit N. Varu |
| Disclosed are pharmaceutical compositions and methods for digesting atherosclerotic plaques in a patient in need thereof. The compositions include and the methods utilize a mixture of collagenases for digesting plaques and optionally may include or utilize additional agents such as cyclodextrins, chelating agents, and tissue plasminogen activator. | ||||||
| 120 | Glycopegylation methods and proteins/peptides produced by the methods | US13246512 | 2011-09-27 | US08853161B2 | 2014-10-07 | Shawn DeFrees; David A. Zopf; Robert J. Bayer; David James Hakes; Caryn Bowe; Xi Chen |
| The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | ||||||
QQ群二维码
意见反馈
意见反馈